ICG Anastomotic Control in Digestive System Surgery

NCT ID: NCT06270745

Last Updated: 2024-02-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2024-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a parallel single-center retrospective cohort study conducted at Linglong Yingcheng Hospital, Shandong, China. The purpose of this study was to investigate the effect of indocyanine green (ICG) on patients undergoing digestive system surgery (subtotal gastrectomy, partial hepatectomy, transverse colectomy, left colectomy, including sigmoid resection, and splenic colic resection). ) of anastomotic leakage (AL). Secondary objectives were to detect and study the impact of various risk factors on AL and on morbidity and surgical performance within 30 days of surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a parallel single-center retrospective cohort study observing a series of consecutive patients who underwent colorectal surgery at our institution between January 1, 2018, and December 31, 2023.

The primary endpoint of the study is AL at 30 days, and the secondary endpoint is postoperative morbidity of Clavien-Dindo score ≥ III within 30 days after surgery, including readmission and redo surgery, lymph node disease in patients with neoplastic disease Harvest, surgical site infection, laparoscopic surgery rate, and protected stoma rate.

According to the American Joint Committee on Cancer (AJJC) 8th edition, gender, body mass index, smoking, diabetes, cardiovascular disease, and tumor stage will be considered confounding factors in the development of AL.

A patient electronic database will be collected from medical records extracted from surgical logs and each digital medical record will be scanned to include perioperative outcomes and post-operative follow-up for 30 days after surgery, final readmission to the emergency room or any other department based on The following inclusion criteria, performed in the specialist ward of our local health institution: elective surgery, left colon segmental surgery: splenic colic resection, transverse colic resection and left hemicolectomy, defined as left hemicolectomy, low Mesenteric artery ligation and sigmoid resection, regardless of benign or malignant pathology, minimum 30 days of postoperative follow-up (available from medical documentation), primary colostomy or colorectal anastomosis with or without prophylactic ostomy ) and age of adulthood.

Exclusion criteria were distal colostomy without anastomosis after removal step, extended transverse right hemicolectomy, left hemicolectomy with high vascular ligation, resection of associated bowel or other viscera (ie, tumor infiltration), previous colic Surgery, synchronous tumors, failure to report vessel ligation in surgery form details, lack of medical record reporting of primary outcome, stage IV cancer, American Society Of Anestheasiologists (ASA) IV, under 18 years of age, and emergencies.

Reconstruction times vary with different anastomoses (colostomy or colorectal), techniques (staplers or hand suturing), and connections (side to side, side to end, end to side, or end to end).

Since 2018, our institute has been using ICG fluorescence laparoscopy, using a near-infrared (NIR) light source and a special oscilloscope and camera equipped with a xenon lamp; ICG is available as a sterile water-soluble lyophilized powder (Diagnostic Green® GmbH) . ICGICG fluorescence laparoscopy is routinely used in daily practice, following the following protocol: after specimen resection and before anastomosis, both colonic stumps or the colon and rectal stumps are examined with 5 cc of ICG 25 mg diluted in 10 cc of sterile aqueous solution .

Statistical analysis and sample size:

Quantitative variables will be described by mean ± standard deviation or median and IQR, and qualitative variables will be described by absolute frequency and percentage frequency. All continuous variables will be checked for normality. Comparisons of covariates will be performed using the Pearson X2 test or Fisher's exact test (for categorical variables) and the t test or Mann Whitney test (for continuous variables). Univariate analysis will be performed using logistic regression to examine the association of each predictor variable with anastomotic leak events. Next, variables with p\<0.1 were considered for inclusion in the multivariable regression model. For each risk factor, the odds ratio is shown along with the associated confidence interval. All analyzes will be performed using spss version 27.0 statistical software with two-sided significance tests and a 5% significance level.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Surgical Anastomosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Indocyanine Green

Indocyanine green infusion during digestive system surgery

indocyanine green

Intervention Type DRUG

Whether to use ICG to assess anastomotic perfusion during digestive system surgery

non-Indocyanine Green

No indocyanine green infusion during digestive system surgery

indocyanine green

Intervention Type DRUG

Whether to use ICG to assess anastomotic perfusion during digestive system surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

indocyanine green

Whether to use ICG to assess anastomotic perfusion during digestive system surgery

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* elective setting of surgery
* digestive system surgery for benign or malignant pathology
* 30 days of post-operative follow-up at least available from medical documentation
* primary colo-colic or colo-rectal anastomosis with or without preventing ostomy
* more than 18 years old, less than 90 years old

Exclusion Criteria

* terminal colonic stoma without anastomosis creation after demolitive step
* extended transverse right hemicolectomy
* left hemicolectomy with high vascular ligation
* associated bowel or another splanchnic resection (i.e. neoplastic infiltration)
* previous colic surgery
* synchronous neoplasm
* not reporting in operating form details about vascular ligation
* lack in reporting in medical records of primary outcomes
* stage IV cancer
* ASA IV
* less than 18 years old, more then 90 years old
* emergency setting
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shandong Linglong Yingcheng Hospital

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xuan Qiu, MD

Role: PRINCIPAL_INVESTIGATOR

Shandong Linglong Yingcheng Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shandong Linglong Yingcheng Hospital

Yantai, Shandong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xuan Qiu, MD

Role: CONTACT

8618354280081

Ni Wang, MD,PD

Role: CONTACT

8618705353551

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xuan Qiu, MD

Role: primary

8618354280081

Ni Wang, MD

Role: backup

8618705353551

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

sdycllyy001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.